ATE412908T1 - Insulinpromotor-faktor 1 als target/marker von beta-zellen-störung - Google Patents

Insulinpromotor-faktor 1 als target/marker von beta-zellen-störung

Info

Publication number: ATE412908T1
Authority: AT; Austria
Prior art keywords: marker; target; beta cell; cell disorder; factor
Prior art date: 2004-07-28

Application number

AT05776018T

Other languages

English (en)

Inventor

Andreas Christ

Stefan Evers

Kurt Krapfenbauer

Elena Sebokova

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-28

Filing date

2005-07-19

Publication date

2008-11-15

2005-07-19 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2008-11-15 Application granted granted Critical

2008-11-15 Publication of ATE412908T1 publication Critical patent/ATE412908T1/de

Links

210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 title abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
239000003550 marker Substances 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 abstract 2
206010061818 Disease progression Diseases 0.000 abstract 1
102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 abstract 1
101710144033 Pancreas/duodenum homeobox protein 1 Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
230000005750 disease progression Effects 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
238000012544 monitoring process Methods 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Immunology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT05776018T 2004-07-28 2005-07-19 Insulinpromotor-faktor 1 als target/marker von beta-zellen-störung ATE412908T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04103611		2004-07-28

Publications (1)

Publication Number	Publication Date
ATE412908T1 true ATE412908T1 (de)	2008-11-15

Family

ID=35229810

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05776018T ATE412908T1 (de)	2004-07-28	2005-07-19	Insulinpromotor-faktor 1 als target/marker von beta-zellen-störung

Country Status (9)

Country	Link
US (1)	US20090208971A1 (de)
EP (1)	EP1774340B1 (de)
JP (1)	JP2008508503A (de)
CN (1)	CN1993620A (de)
AT (1)	ATE412908T1 (de)
CA (1)	CA2574424A1 (de)
DE (1)	DE602005010712D1 (de)
ES (1)	ES2314694T3 (de)
WO (1)	WO2006010530A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100918137B1 (ko) *	2006-10-19	2009-09-17	시니흐 엔터프라이즈 컴퍼니 리미티드	가변 밀도를 갖는 섬유 패드 구조체
CN104098675A (zh) *	2013-04-03	2014-10-15	苏州偲聚生物材料有限公司	多肽、包含该多肽的检测器件和检测试剂盒
CA3092472A1 (en) *	2018-03-02	2019-09-06	Evonik Operations Gmbh	In vitro method for detecting intestinal barrier failure in animals

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003061583A2 (en) *	2002-01-18	2003-07-31	Incyte Genomics Inc.	Digenic mutations associated with severe insulin resistance and type 2 diabetes and their use in the diagnosis and treatment of diabetes
JP2005527203A (ja) *	2002-03-22	2005-09-15	バイエル・フアーマシユーチカルズ・コーポレーシヨン	偽島の調製のための方法
WO2004019983A1 (ja) *	2002-08-30	2004-03-11	Daiichi Pharmaceutical Co.,Ltd.	糖代謝関連遺伝子の転写因子の分解方法、分解阻害方法および分解阻害剤
DE10241111A1 (de) *	2002-09-03	2004-03-11	Ernst-Moritz-Arndt-Universität	Modulation der Insulinsynthese
GB0221686D0 (en) *	2002-09-19	2002-10-30	Univ Ulster	Biomarker

2005
- 2005-07-19 US US11/658,458 patent/US20090208971A1/en not_active Abandoned
- 2005-07-19 JP JP2007522980A patent/JP2008508503A/ja active Pending
- 2005-07-19 ES ES05776018T patent/ES2314694T3/es not_active Expired - Lifetime
- 2005-07-19 WO PCT/EP2005/007854 patent/WO2006010530A1/en not_active Ceased
- 2005-07-19 DE DE602005010712T patent/DE602005010712D1/de not_active Expired - Fee Related
- 2005-07-19 CN CNA2005800256214A patent/CN1993620A/zh active Pending
- 2005-07-19 AT AT05776018T patent/ATE412908T1/de not_active IP Right Cessation
- 2005-07-19 CA CA002574424A patent/CA2574424A1/en not_active Abandoned
- 2005-07-19 EP EP05776018A patent/EP1774340B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US20090208971A1 (en)	2009-08-20
CA2574424A1 (en)	2006-02-02
ES2314694T3 (es)	2009-03-16
CN1993620A (zh)	2007-07-04
DE602005010712D1 (de)	2008-12-11
WO2006010530A1 (en)	2006-02-02
EP1774340A1 (de)	2007-04-18
JP2008508503A (ja)	2008-03-21
EP1774340B1 (de)	2008-10-29

Similar Documents

Publication	Publication Date	Title
Fernández-Lázaro et al.	2022	Potential satellite cell-linked biomarkers in aging skeletal muscle tissue: proteomics and proteogenomics to monitor sarcopenia
DE602006011896D1 (de)	2010-03-11	Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
ATE528300T1 (de)	2011-10-15	Bizyklische verbindungen und ihre verwendung als antidiabetika
ES2572372T3 (es)	2016-05-31	Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
WO2008030273A3 (en)	2008-08-28	Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2008089281A3 (en)	2008-11-20	Methods of treating diabetes
WO2006084101A3 (en)	2007-10-11	Method and apparatus for determining familial risk of disease
EA200870594A1 (ru)	2009-06-30	Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
ATE511857T1 (de)	2011-06-15	Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
EA200701469A1 (ru)	2008-02-28	Комбинированная терапия для лечения диабета и родственных ему состояний и для лечения состояний, улучшаемых увеличением уровня glp-1 крови
EP1547996A4 (de)	2006-08-02	Diagnostische sonden und heilmittel für krankheiten, bei denen prionprotein akkumuliert wird, und anfürbereagenzien für prionprotein
DK2005162T3 (da)	2012-03-05	Screeningsmetode
ATE433115T1 (de)	2009-06-15	Timp-2 als ziel/marker des versagens von beta- zellen
ATE381551T1 (de)	2008-01-15	Diphenylaminsubstituierte salicylthiazolderivate und verwandte verbindungen als phosphotyrosinphosphatase 1b (ptp1b) hemmer zur verwendung als blutzuckersenkende wirkstoffe zur behandlung von diabetes
ATE468535T1 (de)	2010-06-15	Verwendung von nnmt als marker für lungenkrebs
Kronenberg et al.	2020	Increased collagen turnover impairs tendon microstructure and stability in integrin α2β1-deficient mice
ATE412908T1 (de)	2008-11-15	Insulinpromotor-faktor 1 als target/marker von beta-zellen-störung
WO2006010533A3 (en)	2006-08-10	Pancreatic polypeptide as target/marker of beta cell failure
ITRM20050398A1 (it)	2007-01-27	Metodo per la rilevazione di cellule t in pazienti neodiagnosticati per diabete di tipo 1.
WO2006063734A3 (en)	2006-10-12	Integrin (alpha v beta 1) as target/marker for insulin resistance
AU2006228990A8 (en)	2013-02-07	A method of diagnosis and treatment and agents useful for same
WO2006119888A3 (en)	2007-02-01	Butyrylcholinesterase as target/marker for insulin resistance
WO2003103601A3 (en)	2004-09-23	Methods of diagnosing & treating diabetes and insulin resistance
Schramm	2012	Self-monitoring of blood glucose: one STeP forward?
Ehtisham et al.	2019	Accuracy of glucose sensor estimate of HbA1c in children with type 1 diabetes

Legal Events

Date	Code	Title	Description
2009-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties